ep turnov beat estim full year ep guidanc rais narrow
upper end rang
adjust ep estim consensu
guidanc core ep growth narrow cer with/without
gener advair launch vs prior cer advair gener
cer octob advair gener launch estim fx impact unchang
rais estim reflect beat
beyond estim review
turnov estim pharma sale
forecast drug beat estim includ
advair shingrix sale guidanc
rais vs prior tivicay benlysta cervarix flovent
trelegi combin forecast product estim
includ infanrix boostrix hepat vaccin rotarix epzicom anoro
breo/relvar gsk note breo could experi pressur chang
respiratori franchis synflorix triumeq combin light
veramyst line consum sale
gpm estim
estim sg forecast non-oper
incom estim share profits/loss jv
estim interest expens forecast minor interest expens
estim tax rate estim share
count forecast
gsk re-affirmed year growth expect last confirm juli
group sale expect grow low mid singl digit compound-annual-growth-rate adjust ep
mid high singl digit compound-annual-growth-rate chang expect increas vaccin oper
margin rang vs prior off-set slightli lower pharma
margin around vs prior low due increas gsk acknowledg
pipelin need strengthen like done complet organ
trelegi close tripl eu label updat impact copd exacerb posit chmp
pleas see page report import disclosur
gsk share perform tie compani abil deliv growth launch
new drug deal advair pressur breo anoro gain traction
long way go blunt futur gener pressur advair sever new product
earli stage rollout soon launch need achiev success viiv hit big new
competit risk oper restructur provid solid framework return
growth execut key rate gsk market perform pend greater visibl new
product success restructur benefit ep acceler
dolutegravir lamivudin approv tx-
uptak new launch trelegi close
tripl copd shingrix zoster vaccin
progress new strateg initi
advair gener delay and/or
competit
acceler penetr breo anoro
incrus
increas competit pressur hiv
materi
meaning expect
advair gener market near
term and/or competit
breo/anoro gain traction
greater expect pressur hiv
glaxosmithklin global biopharmaceut compani form merger glaxo
wellcom plc smithklin beecham plc gsk lead portfolio respiratori
vaccin product glaxo focu key area vaccin
cowen compani
oper interest ordinari activ tax minor basic mm cowen
cowen compani
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl advair success
pipelin product especi respiratori oncolog hiv success deal
patent litig patent expir pressur particularli involv advair
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock glaxosmithklin plc adr roch hold ltd adr secur
cowen compani act financi advisor acquisit raxibacumab busi glaxosmithklin announc juli
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
